Flagship Pioneering

Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.

Ampersand Biomedicines is a biotechnology company that focuses on developing innovative therapeutic solutions aimed at treating diseases directly at the site of action. Utilizing its proprietary Address, Navigate, Design (AND)™ Platform, the company integrates a localizing element for precision targeting with an actuator tailored for specific disease modification. This approach allows for the exploration and treatment of a wide array of diseases across various areas of the body, enhancing the potential for effective medical interventions.

Lila Sciences is a platform that uses artificial intelligence to support research in life sciences, chemical sciences, and materials sciences. It develops AI-driven tools and autonomous labs to improve research efficiency and facilitate scientific discoveries. The platform is designed to enhance various aspects of the scientific method and contribute to advancements in technology and innovation.

Mirai Bio has developed an open platform powered by AI to address the main drawbacks and manufacturing to develop the future of genetic medicine.

Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Harbinger Health is a biotechnology company focused on the early detection of cancer through a two-tier blood testing model. By integrating artificial intelligence and machine learning, the company aims to identify cancer at its earliest stages, even before symptoms become apparent. This innovative approach seeks to provide low-cost, multi-cancer blood tests that enhance diagnostic capabilities for healthcare professionals, ultimately facilitating more timely and effective interventions for patients.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through the use of beneficial plant microbes. The company leverages a database of genomic microbe information to identify and apply specific microbes that can optimize crop health and yield. By offering these microbes as a seed coating, Indigo aims to help farmers reduce risks associated with crop production, ultimately increasing profitability. In addition to its focus on microbial solutions, Indigo provides various services, including information, advice, assessment, training, and funding, to support farmers in improving their practices. The company's efforts are designed not only to benefit growers but also to contribute to more efficient food production methods, such as reducing water usage and minimizing reliance on nitrogen fertilizers and pesticides.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies through its unique platform. The company specializes in Generative Biology, a machine learning-driven approach that analyzes known proteins to understand the relationship between genetic sequences, protein structure, and function. This enables the creation of novel therapeutic proteins, including antibodies, enzymes, and receptors, which are designed to interact specifically and effectively with various therapeutic targets. Founded in 2018 and rebranded from Generate Biologics in 2020, Generate Biomedicines aims to streamline the drug discovery process by generating new biological molecules with significant therapeutic potential.

Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.

Empress Therapeutics is an early-stage biotechnology company focused on drug development and gaining new molecular insights into health and disease. The company utilizes a proprietary bio platform that integrates evolutionary principles, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules. This innovative approach aims to enable clinicians to address a variety of serious unmet medical needs through the development of small-molecule drug candidates.

Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Ampersand Biomedicines is a biotechnology company that focuses on developing innovative therapeutic solutions aimed at treating diseases directly at the site of action. Utilizing its proprietary Address, Navigate, Design (AND)™ Platform, the company integrates a localizing element for precision targeting with an actuator tailored for specific disease modification. This approach allows for the exploration and treatment of a wide array of diseases across various areas of the body, enhancing the potential for effective medical interventions.

Montai is harnessing nature's power through digital technology to treat and prevent chronic disease, hence improving health outcomes for as many people as possible. To address this crucial global concern, the business is pioneering cutting-edge technology to develop AnthromoleculeTM medications, which are derived from a privileged class of compounds with a history of safe human use. Our human-centered foundation can enable the rapid and repeatable development of safe, efficacious, and accessible medicines for as many diseases and people as possible by creating the world's first Anthromolecule Bioactivity Atlas, which comprehensively maps potent connections to all known biological pathways underlying disease.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, founded in 2017. It focuses on discovering and developing medicines by analyzing cell behaviors through its innovative biomedical platform. This platform utilizes genomic technologies, single-cell data, and advanced machine learning algorithms to digitize and quantify the molecular information in cells, thereby elucidating their behavior in both health and disease. By leveraging this comprehensive understanding of cellular and molecular dynamics, Cellarity aims to design targeted therapies that address the complexities of various diseases, ultimately improving the efficiency and success rates of drug discovery.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Apriori Bio is a health security company dedicated to protecting humanity from viral threats. It employs a unique technology platform that surveys the landscape of existing and potential viral variants, enabling the design of variant-resilient vaccines and antibody drugs. By providing real-time insights, Apriori Bio aims to prepare for future outbreaks and ensure durable protection against rapidly evolving viruses. The company's innovative approach focuses on developing effective solutions to combat both current and emerging viral challenges.

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Vesalius Therapeutics is a biotechnology company dedicated to enhancing the understanding and treatment of diseases responsible for the majority of human illnesses. The company has developed a platform that connects clinical patterns with the interactions of various genes, identifying the genetic circuits that contribute to disease. Additionally, Vesalius creates proprietary patient-derived, cell-based experimental models that allow for the screening and characterization of drug candidates aimed at restoring these genetic circuits to their healthy states. This innovative approach enables healthcare practitioners to recognize previously unobserved clinical patterns among groups of patients, ultimately aiming to improve treatment outcomes for common illnesses.

Harbinger Health is a biotechnology company focused on the early detection of cancer through a two-tier blood testing model. By integrating artificial intelligence and machine learning, the company aims to identify cancer at its earliest stages, even before symptoms become apparent. This innovative approach seeks to provide low-cost, multi-cancer blood tests that enhance diagnostic capabilities for healthcare professionals, ultimately facilitating more timely and effective interventions for patients.

Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential.

CIBO Technologies, Inc. specializes in developing advanced software products that model and simulate agricultural ecosystems to enhance sustainability and productivity in farming. Its offerings include Continuum DB, a distributed database for spatio-temporal modeling, and BarnCAT, a toolkit for analyzing plant and soil sciences. Additionally, CIBO provides WhetherRain, a stochastic weather generator for detailed weather simulations, and DirtPatch, a platform focused on environmental reconstruction. Its Land Intelligence platform delivers insights on agricultural parcels, catering to a diverse clientele in sectors such as farm services, agribusiness, and financial services. By leveraging data science and computational agronomy, CIBO aims to improve grower outcomes and drive the adoption of sustainable agricultural practices, contributing to climate change mitigation and food system resilience. Founded in 2014 and headquartered in Cambridge, Massachusetts, CIBO also has offices in Saint Louis, East Lansing, and Minneapolis.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Laronde is a biopharmaceutical company that specializes in developing eRNA-based therapeutics designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative platform, known as Endless RNA, is characterized by its persistence, non-immunogenic properties, and adaptability for repeat dosing and various delivery methods. This flexibility positions Laronde to support the simultaneous advancement of multiple therapeutic programs across different disease areas, aiming to create more predictable and impactful medicines for patients. The company's approach seeks to redefine the possibilities of therapeutic development, ultimately contributing to the creation of essential medicines for the future.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Invaio Sciences, Inc. is a technology company based in Cambridge, Massachusetts, with additional locations in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Founded in 2016, the company focuses on harnessing the potential of interdependent natural systems to address significant challenges in agriculture, nutrition, and the environment. Invaio Sciences is dedicated to developing innovative technologies grounded in scientific research, aiming to implement transformative solutions that positively impact agriculture, human health, animal nutrition, and animal health.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Laronde is a biopharmaceutical company that specializes in developing eRNA-based therapeutics designed to express a variety of proteins within the body. Founded in 2017 by Flagship Labs, Laronde's innovative platform, known as Endless RNA, is characterized by its persistence, non-immunogenic properties, and adaptability for repeat dosing and various delivery methods. This flexibility positions Laronde to support the simultaneous advancement of multiple therapeutic programs across different disease areas, aiming to create more predictable and impactful medicines for patients. The company's approach seeks to redefine the possibilities of therapeutic development, ultimately contributing to the creation of essential medicines for the future.

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Cellarity Inc is a therapeutics company based in Cambridge, Massachusetts, founded in 2017. It focuses on discovering and developing medicines by analyzing cell behaviors through its innovative biomedical platform. This platform utilizes genomic technologies, single-cell data, and advanced machine learning algorithms to digitize and quantify the molecular information in cells, thereby elucidating their behavior in both health and disease. By leveraging this comprehensive understanding of cellular and molecular dynamics, Cellarity aims to design targeted therapies that address the complexities of various diseases, ultimately improving the efficiency and success rates of drug discovery.

Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Senda Biosciences, founded in 2017 in Cambridge, Massachusetts, focuses on developing therapeutic applications for innovative treatments of human diseases. The company investigates the molecular relationships among bacterial, botanical, and human cells, aiming to understand how these interactions influence health and disease. By leveraging insights from these interspecies connections, Senda Biosciences seeks to create new categories of medicines and delivery methods that can assist medical professionals in providing effective treatments.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through the use of beneficial plant microbes. The company leverages a database of genomic microbe information to identify and apply specific microbes that can optimize crop health and yield. By offering these microbes as a seed coating, Indigo aims to help farmers reduce risks associated with crop production, ultimately increasing profitability. In addition to its focus on microbial solutions, Indigo provides various services, including information, advice, assessment, training, and funding, to support farmers in improving their practices. The company's efforts are designed not only to benefit growers but also to contribute to more efficient food production methods, such as reducing water usage and minimizing reliance on nitrogen fertilizers and pesticides.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Sigilon Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing functional cures for chronic diseases. The company’s lead product candidate, SIG-001, is currently in Phase I/II clinical trials aimed at preventing bleeding episodes in patients with moderate to severe Hemophilia A. In addition to SIG-001, Sigilon is working on SIG-005, which targets the non-neurological manifestations of mucopolysaccharidosis type 1, and SIG-002, designed to replace islet cells in the treatment of type 1 diabetes. Utilizing its Shielded Living Therapeutics platform, Sigilon aims to create immune-protected, engineered human cells that restore normal physiological functions while minimizing issues of fibrosis and immune rejection. The company was founded in 2015 and adopted its current name in June 2017.

Ohana Biosciences is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing innovative molecular techniques aimed at enhancing reproductive health, particularly by focusing on sperm biology rather than egg biology. Ohana's products are designed to improve sperm quality and function, thereby addressing infertility and preventing inherited diseases. Additionally, the company is working on a long-acting, reversible, and non-hormonal male contraceptive. Through its advancements in reproductive medicine, Ohana Biosciences aims to empower individuals and couples to have children on their own terms, while also striving to reduce pregnancy complications.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing gene therapies through its innovative Anellovector platform. This platform leverages the biology of the human commensal virome to create redosable and targetable DNA therapies that address several limitations of existing gene therapies, such as restricted access to various tissues, risks associated with genomic integration, and issues with tolerability. Founded in 2017, the company aims to expand the applications of gene therapy beyond traditional gene replacement, targeting a wide range of conditions including genetic disorders, ophthalmology, oncology, and metabolic diseases. By doing so, Ring Therapeutics seeks to provide healthcare solutions that allow for a broader array of therapeutic modalities and improved patient outcomes.

Invaio Sciences, Inc. is a technology company based in Cambridge, Massachusetts, with additional locations in Durham, North Carolina; Basel, Switzerland; and São Paulo, Brazil. Founded in 2016, the company focuses on harnessing the potential of interdependent natural systems to address significant challenges in agriculture, nutrition, and the environment. Invaio Sciences is dedicated to developing innovative technologies grounded in scientific research, aiming to implement transformative solutions that positively impact agriculture, human health, animal nutrition, and animal health.

Cygnal Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing drugs that manipulate exoneural biology to address cancer, immunological diseases, and regenerative processes. Founded in 2016 by Flagship Pioneering within the VentureLabs innovation foundry, Cygnal harnesses advanced neurotechnology to explore and discover new dimensions of neural function. The company aims to create innovative therapeutic options by leveraging its unique approach to understanding and altering the interactions between the nervous system and various biological processes.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Valo Health, Inc (Valo) is a technology company focused on utilizing large scale data and AI-driven computation to discover and develop therapeutics. Valo aims to fully integrate human-centric data across the entire drug development life cycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing costs, time, and failure rates. The company’s Opal Computational Platform™ is an end-to-end drug discovery and development platform with a unified architecture designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs, initially focused on cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, MA, Valo also has offices in Lexington, MA, and New York, NY. To learn more, visit valohealth.com.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through the use of beneficial plant microbes. The company leverages a database of genomic microbe information to identify and apply specific microbes that can optimize crop health and yield. By offering these microbes as a seed coating, Indigo aims to help farmers reduce risks associated with crop production, ultimately increasing profitability. In addition to its focus on microbial solutions, Indigo provides various services, including information, advice, assessment, training, and funding, to support farmers in improving their practices. The company's efforts are designed not only to benefit growers but also to contribute to more efficient food production methods, such as reducing water usage and minimizing reliance on nitrogen fertilizers and pesticides.

Kaleido Biosciences is a clinical-stage healthcare company that focuses on harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the efficient discovery and development of Microbiome Metabolic Therapies (MMTs). These therapies aim to modify the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates targeting various diseases and conditions that address significant unmet patient needs.

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

Rubius Therapeutics, based in Cambridge, Massachusetts, specializes in the development of red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare diseases, and autoimmune disorders. Founded in 2013, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. The innovative approach of creating RCTs represents a new class of medicines, with applications spanning various serious health conditions. Rubius Therapeutics was established by Flagship VentureLabs, which focuses on transforming scientific innovations into practical medical solutions.

Inzen Therapeutics is a early-stage biotechnology company exploring cellular turnover as a surprising and important driver of disease.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Repertoire Immune Medicines is a clinical-stage biotechnology company founded in 2016 and based in Cambridge, Massachusetts. The company focuses on harnessing the power of T cells to develop innovative therapies aimed at preventing, treating, and curing cancer, autoimmune conditions, and infectious diseases. Repertoire Immune Medicines is actively engaged in experimental clinical trials that utilize autologous T cells primed against specific cancer antigens and linked to IL-15. Additionally, the company specializes in the characterization of T cell receptor (TCR)-antigen pairs, allowing for the rational design and development of targeted immune medicines. These efforts are designed to enhance the human immune system's capabilities, providing new treatment options for patients with serious health challenges.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

KSQ Therapeutics, based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. Founded in 2015, the company employs its proprietary CRISPRomics™ drug discovery engine to gain insights into the role of human genes across various diseases. This comprehensive understanding of disease biology allows KSQ to identify and validate high-confidence, patient-specific drug targets, enhancing the drug development process by focusing on candidates with the greatest therapeutic potential. The company has initiated several preclinical discovery programs aimed at developing novel medications that could significantly improve patient outcomes.

Kaleido Biosciences is a clinical-stage healthcare company that focuses on harnessing the potential of the microbiome to treat diseases and enhance human health. The company has developed a proprietary product platform that enables the efficient discovery and development of Microbiome Metabolic Therapies (MMTs). These therapies aim to modify the metabolic output and profile of the microbiome by influencing the function and distribution of its existing microbes. Kaleido is advancing a diverse pipeline of MMT candidates targeting various diseases and conditions that address significant unmet patient needs.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.

Evelo Biosciences is a biotechnology company focused on discovering and developing oral biologics known as monoclonal microbials for the treatment of inflammatory diseases and cancer. These innovative medicines are designed to modulate systemic immunology through direct interactions with human cells in the gut, offering potential applications across a wide range of conditions, including autoimmune and neuroinflammatory diseases, as well as various cancers. Evelo's lead product, EDP1815, is currently undergoing clinical trials for psoriasis and atopic dermatitis, while other candidates are in preclinical stages for conditions such as psoriatic arthritis, asthma, and colorectal cancer. Founded in 2014 and based in Cambridge, Massachusetts, Evelo aims to enhance the efficiency and effectiveness of drug discovery by leveraging naturally occurring microbial entities with defined therapeutic effects.

Rubius Therapeutics, based in Cambridge, Massachusetts, specializes in the development of red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare diseases, and autoimmune disorders. Founded in 2013, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. The innovative approach of creating RCTs represents a new class of medicines, with applications spanning various serious health conditions. Rubius Therapeutics was established by Flagship VentureLabs, which focuses on transforming scientific innovations into practical medical solutions.

CIBO Technologies, Inc. specializes in developing advanced software products that model and simulate agricultural ecosystems to enhance sustainability and productivity in farming. Its offerings include Continuum DB, a distributed database for spatio-temporal modeling, and BarnCAT, a toolkit for analyzing plant and soil sciences. Additionally, CIBO provides WhetherRain, a stochastic weather generator for detailed weather simulations, and DirtPatch, a platform focused on environmental reconstruction. Its Land Intelligence platform delivers insights on agricultural parcels, catering to a diverse clientele in sectors such as farm services, agribusiness, and financial services. By leveraging data science and computational agronomy, CIBO aims to improve grower outcomes and drive the adoption of sustainable agricultural practices, contributing to climate change mitigation and food system resilience. Founded in 2014 and headquartered in Cambridge, Massachusetts, CIBO also has offices in Saint Louis, East Lansing, and Minneapolis.

Oasys Water, Inc. is a Boston-based company that specializes in forward osmosis technology aimed at reducing the cost of producing clean water. Founded in 2008, it has developed a platform called Engineered Osmosis, which incorporates forward osmosis and a draw solution recovery technique to make salt water treatment more economical. The company focuses on providing integrated membrane systems for high recovery desalination, brine management, and zero liquid discharge solutions. Through its innovative technologies, Oasys Water addresses the global water crisis by promoting more efficient and sustainable resource utilization, enabling industries to enhance their operational efficiencies while minimizing environmental impact. In addition to its Boston headquarters, Oasys Water also has an office in Dubai.

Boragen Inc. is a biotechnology company based in Durham, North Carolina, founded in 2015. The company specializes in developing multi-functional small molecule boron solutions for applications in crop protection, animal health, and human health. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide aimed at crop protection, and BN2266, a fungicide that targets mRNA processing. Additionally, the company is working on a dual-function nematicide-fungicide for root protection and endo-parasiticides designed to overcome resistance. Boragen's innovative synthetic chemistry platform focuses on creating next-generation fungicides that support sustainable farming by minimizing the risk of fungicide resistance and reducing chemical usage while ensuring efficacy and performance.

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

Incredible Foods strives to develop unique, all-inclusive products that are delicious, fun to eat and enhance the lives of those who enjoy them. Through its perfectly free™ brand, the Company is committed to creating delicious "Big 8 Allergy-Friendly™" foods for everyone who desire a fuller, happier, healthier, free-from lifestyle. perfectly free™ contain only natural, premium ingredients that are non-GMO and free from the Big 8 food allergens: dairy, wheat, peanuts, tree nuts, eggs, soy, fish and shellfish. All products are prepared in a dedicated, free-from facility.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through the use of beneficial plant microbes. The company leverages a database of genomic microbe information to identify and apply specific microbes that can optimize crop health and yield. By offering these microbes as a seed coating, Indigo aims to help farmers reduce risks associated with crop production, ultimately increasing profitability. In addition to its focus on microbial solutions, Indigo provides various services, including information, advice, assessment, training, and funding, to support farmers in improving their practices. The company's efforts are designed not only to benefit growers but also to contribute to more efficient food production methods, such as reducing water usage and minimizing reliance on nitrogen fertilizers and pesticides.

TransMedics Group Inc is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage organ failure. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to replicate near-physiologic conditions for donor organs outside the human body. This innovative system addresses the limitations associated with traditional cold storage organ preservation, enhancing clinical outcomes and increasing transplant volumes. By providing advanced technology and clinical service solutions, TransMedics aims to improve the overall effectiveness of heart and lung transplant procedures, thereby reducing learning curves for medical professionals involved in organ transplantation.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

TransMedics Group Inc is a commercial-stage medical technology company focused on transforming organ transplant therapy for patients with end-stage organ failure. The company has developed the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system designed to replicate near-physiologic conditions for donor organs outside the human body. This innovative system addresses the limitations associated with traditional cold storage organ preservation, enhancing clinical outcomes and increasing transplant volumes. By providing advanced technology and clinical service solutions, TransMedics aims to improve the overall effectiveness of heart and lung transplant procedures, thereby reducing learning curves for medical professionals involved in organ transplantation.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through the use of beneficial plant microbes. The company leverages a database of genomic microbe information to identify and apply specific microbes that can optimize crop health and yield. By offering these microbes as a seed coating, Indigo aims to help farmers reduce risks associated with crop production, ultimately increasing profitability. In addition to its focus on microbial solutions, Indigo provides various services, including information, advice, assessment, training, and funding, to support farmers in improving their practices. The company's efforts are designed not only to benefit growers but also to contribute to more efficient food production methods, such as reducing water usage and minimizing reliance on nitrogen fertilizers and pesticides.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Rubius Therapeutics, based in Cambridge, Massachusetts, specializes in the development of red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare diseases, and autoimmune disorders. Founded in 2013, the company is advancing several therapeutic candidates, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. The innovative approach of creating RCTs represents a new class of medicines, with applications spanning various serious health conditions. Rubius Therapeutics was established by Flagship VentureLabs, which focuses on transforming scientific innovations into practical medical solutions.

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Evelo Biosciences is a biotechnology company focused on discovering and developing oral biologics known as monoclonal microbials for the treatment of inflammatory diseases and cancer. These innovative medicines are designed to modulate systemic immunology through direct interactions with human cells in the gut, offering potential applications across a wide range of conditions, including autoimmune and neuroinflammatory diseases, as well as various cancers. Evelo's lead product, EDP1815, is currently undergoing clinical trials for psoriasis and atopic dermatitis, while other candidates are in preclinical stages for conditions such as psoriatic arthritis, asthma, and colorectal cancer. Founded in 2014 and based in Cambridge, Massachusetts, Evelo aims to enhance the efficiency and effectiveness of drug discovery by leveraging naturally occurring microbial entities with defined therapeutic effects.

TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, it is focused on discovering and developing innovative genome editing therapeutics to address a wide range of serious diseases. The company utilizes a proprietary platform based on CRISPR/Cas9 technology, which employs a protein-RNA complex to target and modify specific DNA sequences for therapeutic purposes. Editas Medicine aims to translate its advanced genome editing technologies into human therapeutics that can provide precise and corrective molecular modifications to treat genetic disorders. With a strong foundation of patent filings and intellectual property, the company is positioned to advance its early findings into viable treatments for various diseases at the genetic level.

Axcella is a clinical-stage biotechnology company dedicated to addressing complex diseases through the use of endogenous metabolic modulator (EMM) compositions. By integrating biological pathways with advancements in systems biology and machine learning, Axcella aims to identify protein nutrients in the human diet that possess significant pharmacological effects. The company has developed a proprietary platform that has been clinically validated across various indication areas, including muscle, neurodegenerative, and liver conditions. Axcella's innovative approach seeks to enhance health outcomes by leveraging the therapeutic potential of EMMs.

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Joule Unlimited, Inc. is a company focused on producing infrastructure-compatible fuels using solar energy and waste carbon dioxide. Founded in 2007 and headquartered in Cambridge, Massachusetts, with an additional office in Los Angeles, the company utilizes photosynthetic microorganisms as living catalysts to convert CO2 directly into sustainable liquid fuels, such as diesel and ethanol. Joule Unlimited's innovative approach enables the recycling of greenhouse gases, turning them into valuable hydrocarbon fuels and contributing to renewable fuel and chemical production. Formerly known as Joule Biotechnologies, Inc., the company rebranded in 2010 to reflect its broader focus on sustainable energy solutions.

Red Rock Biofuels (RRB) develops processing plants to convert woody biomass into renewable, drop-in diesel and jet fuels. Each refinery is designed to utilize 175,000 dry tons of woody biomass feedstock to produce 16 million gallons per year of finished products. RRB’s technology platform converts woody biomass to jet, diesel, and naphtha fuels. The process begins with the gasification of woody biomass to produce synthesis gas. This synthesis gas is cleaned and sent to a Fischer-Tropsch unit where it is converted to liquid hydrocarbons. Hydroprocessing refines the liquid hydrocarbons to produce jet, diesel, and naptha fuels. Red Rock Biofuels was founded by Jeff Manternach and Terry Kulesa and is based in Colorado, United States.

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

EcoSense Lighting specializes in advanced LED lighting solutions tailored for architectural and commercial applications. With over 100 years of combined experience, the company is recognized for its innovative technology, including a breakthrough dimming capability and advanced control systems that integrate seamlessly with various protocols such as DALI, DMX, 0-10V, and ELV. This integration allows businesses to enhance energy efficiency and achieve significant cost savings. EcoSense operates globally, with offices in the United States, the United Kingdom, and Hong Kong, and maintains its headquarters in Los Angeles. The company's commitment to quality and innovation positions it as a leader in the lighting industry.

Seres Therapeutics is a clinical-stage biotherapeutic company based in Cambridge, Massachusetts, that specializes in developing ecobiotic microbiome therapeutics aimed at restoring health by correcting dysbiosis in the microbiome. The company is advancing several product candidates, with its lead therapy, SER-109, currently in Phase III clinical trials to prevent recurrence of Clostridium difficile infection (CDI). Additional candidates in development include SER-287 for ulcerative colitis, SER-401 for use with checkpoint inhibitors in metastatic melanoma, and SER-301 for inflammatory bowel disease. The company is also working on SER-262 to address initial CDI recurrences and SER-155 to support patients after allogeneic hematopoietic stem cell transplants. Seres Therapeutics has established collaboration agreements with organizations such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as partnerships with AstraZeneca. Founded in 2010, the company has evolved from its original name, Seres Health, Inc., reflecting its focus on microbiome-based therapeutic solutions.

Indigo is an agricultural technology company dedicated to enhancing the sustainability and productivity of agriculture through the use of beneficial plant microbes. The company leverages a database of genomic microbe information to identify and apply specific microbes that can optimize crop health and yield. By offering these microbes as a seed coating, Indigo aims to help farmers reduce risks associated with crop production, ultimately increasing profitability. In addition to its focus on microbial solutions, Indigo provides various services, including information, advice, assessment, training, and funding, to support farmers in improving their practices. The company's efforts are designed not only to benefit growers but also to contribute to more efficient food production methods, such as reducing water usage and minimizing reliance on nitrogen fertilizers and pesticides.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Selecta Biosciences, a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializes in the research and development of nanoparticle immunomodulatory drugs aimed at treating and preventing human diseases. The company utilizes its proprietary ImmTOR immune tolerance platform to create targeted immunomodulatory nanoparticles that address undesired immune responses. Its lead product, SEL-212, has completed Phase II clinical trials for chronic refractory gout. Additionally, Selecta is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. The company collaborates with various partners, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development endeavors. Founded in 2007, Selecta Biosciences is committed to innovating therapeutic solutions in the biopharmaceutical landscape.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Black Duck secures and manages open source software worldwide, eliminating open source security vulnerabilities and license compliance pain. With the rapid, widespread adoption of open-source software, Black Duck is a key component of Synopsys’ Software Integrity Platform, the most comprehensive solution for integrating security into the SDLC and software supply chain. Black Duck was established in 2002 and is based in Burlington, Massachusetts, United States.